Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex

Seung Rim Hwang,1 Dong-Hyun Seo,2 Youngro Byun,3 Jin Woo Park4 1Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, 2Department of Biomedical Engineering, College of Health Science, Yonsei University, Wonju, Gangwon, 3Department of Molecular Medicine and Biopharmaceutical Scien...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hwang SR, Seo DH, Byun Y, Park JW
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	oral delivery parathyroid hormone nanocomplex deoxycholic acid coaxial ultrasonic atomization osteoporosis Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/c172829dcf124fe8ab33a3d2c18eb752
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c172829dcf124fe8ab33a3d2c18eb752
record_format	dspace
spelling	oai:doaj.org-article:c172829dcf124fe8ab33a3d2c18eb7522021-12-02T00:31:21ZPreparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex1178-2013https://doaj.org/article/c172829dcf124fe8ab33a3d2c18eb7522016-08-01T00:00:00Zhttps://www.dovepress.com/preparation-and-in-vivo-evaluation-of-an-orally-available-enteric-micr-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Seung Rim Hwang,1 Dong-Hyun Seo,2 Youngro Byun,3 Jin Woo Park4 1Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, 2Department of Biomedical Engineering, College of Health Science, Yonsei University, Wonju, Gangwon, 3Department of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, College of Pharmacy, Seoul National University, Seoul, 4Department of Pharmacy, College of Pharmacy and Natural Medicine Research Institute, Mokpo National University, Muan-gun, Jeonnam, Republic of Korea Abstract: The N-terminal 34-amino-acid peptide fragment of human parathyroid hormone PTH (1-34), is used clinically to treat osteoporosis; however, it is currently administered by a once-daily subcutaneous injection, resulting in poor patient compliance. We have developed enteric microcapsules containing an ionic nanocomplex between PTH (1-34) and lysine-linked deoxycholic acid (LysDOCA) for the oral delivery of PTH (1-34). We measured the particle size of the PTH/LysDOCA complex and assessed its biological activity by determining the cAMP content in MC3T3-E1 cells. We also assessed its permeability across a Caco-2 cell monolayer and the bioavailability of the intrajejunally administered PTH/LysDOCA complex compared with PTH (1-34) in rats. In addition, the antiosteoporotic activity of the PTH/LysDOCA complex, encapsulated in an enteric carrier by coaxial ultrasonic atomization, was evaluated after it was orally administered to ovariectomized (OVX) rats. The formation of an ionic complex between PTH (1-34) and LysDOCA produced nanoparticles of diameter 33.0±3.36 nm, and the bioactivity of the complex was comparable with that of PTH (1-34). The Caco-2 cell permeability and AUClast value of the PTH/LysDOCA (1:10) nanocomplex increased by 2.87- and 16.3-fold, respectively, compared with PTH (1-34) alone. Furthermore, the OVX rats treated with oral PTH/LysDOCA-loaded enteric microcapsules showed an increase in bone mineral density (159%), bone volume fraction (175%), and trabecular number (174%) compared with those in the OVX control group. Therefore, the PTH/LysDOCA nanocomplex oral delivery system is a promising treatment modality for osteoporosis because it improves osteogenesis and trabecular connectivity. Keywords: oral delivery, parathyroid hormone, nanocomplex, deoxycholic acid, coaxial ultrasonic atomization, osteoporosisHwang SRSeo DHByun YPark JWDove Medical Pressarticleoral deliveryparathyroid hormonenanocomplexdeoxycholic acidcoaxial ultrasonic atomizationosteoporosisMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 11, Pp 4231-4246 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	oral delivery parathyroid hormone nanocomplex deoxycholic acid coaxial ultrasonic atomization osteoporosis Medicine (General) R5-920
spellingShingle	oral delivery parathyroid hormone nanocomplex deoxycholic acid coaxial ultrasonic atomization osteoporosis Medicine (General) R5-920 Hwang SR Seo DH Byun Y Park JW Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex
description	Seung Rim Hwang,1 Dong-Hyun Seo,2 Youngro Byun,3 Jin Woo Park4 1Department of Pharmacy, College of Pharmacy, Chosun University, Gwangju, 2Department of Biomedical Engineering, College of Health Science, Yonsei University, Wonju, Gangwon, 3Department of Molecular Medicine and Biopharmaceutical Science, Graduate School of Convergence Science and Technology, College of Pharmacy, Seoul National University, Seoul, 4Department of Pharmacy, College of Pharmacy and Natural Medicine Research Institute, Mokpo National University, Muan-gun, Jeonnam, Republic of Korea Abstract: The N-terminal 34-amino-acid peptide fragment of human parathyroid hormone PTH (1-34), is used clinically to treat osteoporosis; however, it is currently administered by a once-daily subcutaneous injection, resulting in poor patient compliance. We have developed enteric microcapsules containing an ionic nanocomplex between PTH (1-34) and lysine-linked deoxycholic acid (LysDOCA) for the oral delivery of PTH (1-34). We measured the particle size of the PTH/LysDOCA complex and assessed its biological activity by determining the cAMP content in MC3T3-E1 cells. We also assessed its permeability across a Caco-2 cell monolayer and the bioavailability of the intrajejunally administered PTH/LysDOCA complex compared with PTH (1-34) in rats. In addition, the antiosteoporotic activity of the PTH/LysDOCA complex, encapsulated in an enteric carrier by coaxial ultrasonic atomization, was evaluated after it was orally administered to ovariectomized (OVX) rats. The formation of an ionic complex between PTH (1-34) and LysDOCA produced nanoparticles of diameter 33.0±3.36 nm, and the bioactivity of the complex was comparable with that of PTH (1-34). The Caco-2 cell permeability and AUClast value of the PTH/LysDOCA (1:10) nanocomplex increased by 2.87- and 16.3-fold, respectively, compared with PTH (1-34) alone. Furthermore, the OVX rats treated with oral PTH/LysDOCA-loaded enteric microcapsules showed an increase in bone mineral density (159%), bone volume fraction (175%), and trabecular number (174%) compared with those in the OVX control group. Therefore, the PTH/LysDOCA nanocomplex oral delivery system is a promising treatment modality for osteoporosis because it improves osteogenesis and trabecular connectivity. Keywords: oral delivery, parathyroid hormone, nanocomplex, deoxycholic acid, coaxial ultrasonic atomization, osteoporosis
format	article
author	Hwang SR Seo DH Byun Y Park JW
author_facet	Hwang SR Seo DH Byun Y Park JW
author_sort	Hwang SR
title	Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex
title_short	Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex
title_full	Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex
title_fullStr	Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex
title_full_unstemmed	Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex
title_sort	preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/c172829dcf124fe8ab33a3d2c18eb752
work_keys_str_mv	AT hwangsr preparationandinvivoevaluationofanorallyavailableentericmicroencapsulatedparathyroidhormone134deoxycholicacidnanocomplex AT seodh preparationandinvivoevaluationofanorallyavailableentericmicroencapsulatedparathyroidhormone134deoxycholicacidnanocomplex AT byuny preparationandinvivoevaluationofanorallyavailableentericmicroencapsulatedparathyroidhormone134deoxycholicacidnanocomplex AT parkjw preparationandinvivoevaluationofanorallyavailableentericmicroencapsulatedparathyroidhormone134deoxycholicacidnanocomplex
_version_	1718403704361582592

Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex

Ejemplares similares